Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

A S Coates, E P Winer, A Goldhirsch, R D Gelber, M Gnant, M Piccart-Gebhart, B Thürlimann, H-J Senn, Panel Members, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Harold Burstein, Fatima Cardoso, Monica Castiglione-Gertsch, Alan S Coates, Marco Colleoni, Giuseppe Curigliano, Nancy E Davidson, Angelo Di Leo, Bent Ejlertsen, John F Forbes, Viviana Galimberti, Richard D Gelber, Michael Gnant, Aron Goldhirsch, Pamela Goodwin, Nadia Harbeck, Daniel F Hayes, Jens Huober, Clifford A Hudis, James N Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C Kent Osborne, Ann H Partridge, Lorena de la Peña, Martine J Piccart-Gebhart, Kathleen I Pritchard, Emiel J T Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Zhi-Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gunter von Minckwitz, Toru Watanabe, Timothy Whelan, Eric P Winer, Binghe Xu, A S Coates, E P Winer, A Goldhirsch, R D Gelber, M Gnant, M Piccart-Gebhart, B Thürlimann, H-J Senn, Panel Members, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Harold Burstein, Fatima Cardoso, Monica Castiglione-Gertsch, Alan S Coates, Marco Colleoni, Giuseppe Curigliano, Nancy E Davidson, Angelo Di Leo, Bent Ejlertsen, John F Forbes, Viviana Galimberti, Richard D Gelber, Michael Gnant, Aron Goldhirsch, Pamela Goodwin, Nadia Harbeck, Daniel F Hayes, Jens Huober, Clifford A Hudis, James N Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C Kent Osborne, Ann H Partridge, Lorena de la Peña, Martine J Piccart-Gebhart, Kathleen I Pritchard, Emiel J T Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Zhi-Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gunter von Minckwitz, Toru Watanabe, Timothy Whelan, Eric P Winer, Binghe Xu

Abstract

The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation of regional nodes in node-positive disease. Considering subdivisions within luminal disease, the Panel was more concerned with indications for the use of specific therapies, rather than surrogate identification of intrinsic subtypes as measured by multiparameter molecular tests. For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy. For premenopausal patients with endocrine responsive disease, the Panel endorsed the role of ovarian function suppression with either tamoxifen or exemestane for patients at higher risk. The Panel noted the value of an LHRH agonist given during chemotherapy for premenopausal women with ER-negative disease in protecting against premature ovarian failure and preserving fertility. The Panel noted increasing evidence for the prognostic value of commonly used multiparameter molecular markers, some of which also carried prognostic information for late relapse. The Panel noted that the results of such tests, where available, were frequently used to assist decisions about the inclusion of cytotoxic chemotherapy in the treatment of patients with luminal disease, but noted that threshold values had not been established for this purpose for any of these tests. Multiparameter molecular assays are expensive and therefore unavailable in much of the world. The majority of new breast cancer cases and breast cancer deaths now occur in less developed regions of the world. In these areas, less expensive pathology tests may provide valuable information. The Panel recommendations on treatment are not intended to apply to all patients, but rather to establish norms appropriate for the majority. Again, economic considerations may require that less expensive and only marginally less effective therapies may be necessary in less resourced areas. Panel recommendations do not imply unanimous agreement among Panel members. Indeed, very few of the 200 questions received 100% agreement from the Panel. In the text below, wording is intended to convey the strength of Panel support for each recommendation, while details of Panel voting on each question are available in supplementary Appendix S2, available at Annals of Oncology online.

Keywords: St Gallen Consensus; early breast cancer; radiation therapy; surgery; systemic adjuvant therapies.

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

References

    1. Ferlay J, Soerjomataram I, Ervik M et al. . GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide. 2013. Lyon, International Agency for Research on Cancer. IARC CancerBase No. 11.
    1. Coates AS. Evolution of the St. Gallen Consensus process for the optimal treatment of women with breast cancer. Breast 2015; 24(Suppl 1): PG 0.1.
    1. Pagani O, Regan MM, Walley BA et al. . Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107–118.
    1. Francis PA, Regan MM, Fleming GF et al. . Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436–446.
    1. Moore HCF, Unger JM, Phillips KA et al. . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923–932.
    1. Dengel LT, Van Zee KJ, King TA et al. . Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol 2014; 21: 22–27.
    1. Moran MS, Schnitt SJ, Giuliano AE et al. . Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014; 32: 1507–1515.
    1. Whelan T, Olivotto I, Ackerman I. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. In Proceedings of the American Society of Clinical Oncology J Clin Oncol 2011; 29(Suppl): abstr LBA 1003.
    1. Poortmans P, Struikmans S, Collette S. Lymph node radiotherapy improves survival in breast cancer: 10 year results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922/10925. 6. ESTRO Congress Report 2013.
    1. Nordenskjold AE, Fohlin HI, Albertsson P et al. . No clear effect of postoperative radiotherapy on survival of breast cancer patients with 1–3 positive nodes: a population-based study. Ann Oncol 2015; 26: 1149–1154.
    1. Whelan TJ, Pignol JP, Levine MN et al. . Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–520.
    1. Haviland JS, Owen JR, Dewar JA et al. . The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14: 1086–1094.
    1. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
    1. Sorlie T, Perou CM, Tibshirani R et al. . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–10874.
    1. Bastien RR, Rodriguez-Lescure A, Ebbert MT et al. . PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012; 5: 44.
    1. Bayraktar S, Royce M, Stork-Sloots L et al. . Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol 2014; 31: 163.
    1. Dowsett M, Sestak I, Lopez-Knowles E et al. . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783–2790.
    1. Eiermann W, Rezai M, Kummel S et al. . The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013; 24: 618–624.
    1. Prat A, Cheang MC, Martin M et al. . Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31: 203–209.
    1. Nielsen TO, Parker JS, Leung S et al. . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222–5232.
    1. Coates AS, Millar EK, O'Toole SA et al. . Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res 2012; 14: R143.
    1. Regan MM, Pagani O, Walley B et al. . Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008; 19: 1231–1241.
    1. Wirapati P, Sotiriou C, Kunkel S et al. . Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
    1. de Azambuja E, Cardoso F, de Castro G Jr et al. . Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504–1513.
    1. Criscitiello C, Disalvatore D, De Laurentiis M et al. . High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. Breast 2014; 23: 69–75.
    1. Denkert C, von Minckwitz G. Reply to Ki67 in breast cancer: a useful prognostic marker! Ann Oncol 2014; 25: 542–543.
    1. Polley MY, Leung SC, McShane LM et al. . An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897–1906.
    1. Bouganim N, Tsvetkova E, Clemons M et al. . Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat 2013; 139: 603–606.
    1. Houssami N, Morrow M. Margins in breast conservation: a clinician's perspective and what the literature tells us. J Surg Oncol 2014; 110: 2–7.
    1. Giuliano AE, Hunt KK, Ballman KV et al. . Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569–575.
    1. Donker M, van Tienhoven G, Straver ME et al. . Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 1303–1310.
    1. Wolmark N, Mamounas EP, Baehner FL et al. . Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. J Clin Oncol 2014; 32(5s suppl): abstr 11024.
    1. Nielsen T, Wallden B, Schaper C et al. . Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 2014; 14: 177.
    1. Sestak I, Cuzick J, Dowsett M et al. . Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. J Clin Oncol 2015; 33: 916–922.
    1. Sestak I, Dowsett M, Zabaglo L et al. . Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst Monogr 2013; 105: 1504–1511.
    1. Dubsky P, Brase JC, Jakesz R et al. . The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013; 109: 2959–2964.
    1. Zhang Y, Schnabel CA, Schroeder BE et al. . Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013; 19: 4196–4205.
    1. Del Mastro L, Boni L, Michelotti A et al. . Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. JAMA 2011; 306: 269–276.
    1. Gerber B, von Minckwitz MG, Stehle H et al. . Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334–2341.
    1. Sledge GW, Hudis CA, Swain SM et al. . ASCO's approach to a learning health care system in oncology. J Oncol Pract 2013; 9: 145–148.
    1. Campbell P. Interpreting genomics data at a functional level: what are we learning from large molecular screening projects? Breast 2015; 24(Suppl 1): PG 2.01.
    1. Viale G, Slaets L, Bogaerts J et al. . High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol 2014; 25: 816–823.
    1. Reis-Filho J, Weigelt B. Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa. Breast 2015; 24(Suppl 1): PG 2.03.
    1. Maisonneuve P, Disalvatore D, Rotmensz N et al. . Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014; 16: R65.
    1. Viale G. A bad tumor biomarker is as bad as a bad drug: the gap between genomics data and phenotype to predict response. Breast 2015; 24(Suppl 1): PG 2.04.
    1. Prat A, Bianchini G, Thomas M et al. . Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014; 20: 511–521.
    1. Schneeweiss A, Chia S, Hickish T et al. . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278–2284.
    1. Schneeweiss A, Chia S, Hegg R et al. . Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res 2014; 16: R73.
    1. Prat A, Adamo B, Cheang MC et al. . Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18: 123–133.
    1. Loibl S. Primary systemic therapy for clinicians: medical and research perspectives. Breast 2015; 24(Suppl 1): PG 8.01.
    1. Masuda H, Baggerly KA, Wang Y et al. . Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19: 5533–5540.
    1. Lehmann BD, Bauer JA, Chen X et al. . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750–2767.
    1. Adams S, Gray RJ, Demaria S et al. . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959–2966.
    1. Loi S, Michiels S, Salgado R et al. . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544–1550.
    1. Perez EA, Ballman KV, Anderson SK et al. . Stromal tumor-infiltrating lymphocytes (S-TILs): in the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit. Cancer Res 2015; 75: abstr S1-06.
    1. Milagre CS, Gopinathan G, Everitt G et al. . Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer. Cancer Res 2015; 75: 1255–1264.
    1. Herbst RS, Soria JC, Kowanetz M et al. . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–567.
    1. Curigliano G. Immune pathways and immunome as a target. Breast 2015; 24(Suppl 1), PG 4.02.
    1. Nanda R, Chow LQ, Dees EC et al. . A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res Suppl 2015;(Suppl): S1-09.
    1. Finn RS, Crown JP, Lang I et al. . The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25–35.
    1. Telli ML, Jensen KC, Vinayak S et al. . Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 2015. Apr 6 [epub ahead of print], pii: JCO.2014.57.0085.
    1. von Minckwitz G, Hahnen E, Fasching PA et al. . Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto. J Clin Oncol 2014; 32(5s): abstr 1005.
    1. Tutt A, Ellis P, Kilburn LS et al. . TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer CRUK/07/012). Cancer Res Suppl 2014; 75: S3-01.
    1. Baselga J. Targeting PIK3CA pathway. Breast 2015; 24(Suppl 1): PG 5.03.
    1. Andre F, Bachelot T, Campone M et al. . Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19: 3693–3702.
    1. Soria JC, DeBraud F, Bahleda R et al. . Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014; 25: 2244–2251.
    1. Phillips KA, Milne RL, Rookus MA et al. . Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013; 31: 3091–3099.
    1. Hartmann LC, Degnim AC, Santen RJ et al. . Atypical hyperplasia of the breast—risk assessment and management options. N Engl J Med 2015; 372: 78–89.
    1. Yi M, Huo L, Koenig KB et al. . Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 2014; 25: 1004–1011.
    1. Feng Q, Zhang Z, Shea MJ et al. . An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res 2014; 24: 809–819.
    1. Denkert C, Loibl S, Müller BM et al. . Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24: 2786–2793.
    1. Denkert C. Developing Ki67 as a useful marker. Breast 2015; 24(Suppl 1), PG 7.04.
    1. Polley MY, Leung SC, Gao D et al. . An international study to increase concordance in Ki67 scoring. Mod Pathol 2015; 28: 778–786.
    1. Klauschen F, Wienert S, Schmitt W et al. . Standardized Ki67 diagnostics using automated scoring—clinical validation in the GeparTrio Breast Cancer study. Clin Cancer Res 2014. Dec 11 [epub ahead of print], pii: clincanres.1283.2014.
    1. Sikov WM, Berry DA, Perou CM et al. . Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13–21.
    1. von Minckwitz G, Schneeweiss A, Loibl S et al. . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15: 747–756.
    1. Denkert C, von Minckwitz G, Brase JC et al. . Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33: 983–991.
    1. Loibl S, von Minckwitz G, Schneeweiss A et al. . PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32: 3212–3220.
    1. Majewski IJ, Nuciforo P, Mittempergher L et al. . PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 2015; 33: 1334–1339.
    1. Guarneri V, Dieci M, Carbognin L et al. . Activity of neoadjuvant lapatinib plus trastuzumab for early breast cancer according to PIK3CA mutations: pathological complete response (pCR) rate in the CherLOB study and pooled analysis of randomized trials. Ann Oncol 2014; 25(Suppl 4): iv85–iv109.
    1. Allevi G, Strina C, Andreis D et al. . Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer 2013; 108: 1587–1592.
    1. Dowsett M, Smith IE, Ebbs SR et al. . Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167–170.
    1. Dowsett M. Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints. Breast 2015; 24(Suppl 1): PG 8.02.
    1. de Azambuja E, Holmes AP, Piccart-Gebhart M et al. . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014; 15: 1137–1146.
    1. Piccart-Gebhart MJ, Holmes AP, Baselga J et al. . First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T->L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2015; 32(Suppl 15), LBA 4.
    1. DeMichele A, Yee D, Berry DA et al. . The neoadjuvant model is still the future for drug development in breast cancer. Clin Cancer Res 2015; 21: 2911–2915.
    1. Yao K, Winchester DJ, Czechura T et al. . Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002. Breast Cancer Res Treat 2013; 142: 465–476.
    1. Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat 2011; 128: 581–583.
    1. Kurian AW, Lichtensztajn DY, Keegan TH et al. . Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 2014; 312: 902–914.
    1. Guth U, Myrick ME, Viehl CT et al. . Increasing rates of contralateral prophylactic mastectomy—a trend made in USA? Eur J Surg Oncol 2012; 38: 296–301.
    1. Partridge AH, Gelber S, Piccart-Gebhart MJ et al. . Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 2013; 31: 2692–2698.
    1. Kuehn T, Bauerfeind I, Fehm T et al. . Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609–618.
    1. Boileau JF, Poirier B, Basik M et al. . Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol 2015; 33: 258–264.
    1. Boughey JC, Suman VJ, Mittendorf EA et al. . Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 2015; 261: 547–552.
    1. Galimberti V. Feasibility of sentinel node biopsy in breast cancer after neoadjuvant treatment. Breast 2015; 24(Suppl 1), PG 9.02.
    1. Ataseven B, Lederer B, Blohmer JU et al. . Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 2015; 22: 1118–1127.
    1. Yarnold J. Hypofractionated radiotherapy in early breast cancer: clinical, dosimetric and radio-genomic issues. Breast 2015; 24(Suppl 1): PG 10.01.
    1. Whelan T. Evolving standards in breast cancer radiotherapy: who should receive locoregional RT? Breast 2015; 24(Suppl 1): PG 10.02.
    1. Thorsen LB, Thomsen MS, Berg M et al. . CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects. Acta Oncol 2014; 53: 1027–1034.
    1. Gnant M, Mlineritsch B, Stoeger H et al. . Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313–320.
    1. Tevaarwerk AJ, Wang M, Zhao F et al. . Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32: 3948–3958.
    1. Ribi K, Luo W, Francis P et al. . Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: adjuvant treatment with tamoxifen (T) alone versus T plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). Cancer Res Suppl 2014; S3-09.
    1. Bernhard J, Luo W, Ribi K et al. . Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2015; 32(Suppl 15): #557.
    1. Regan M. Predicting benefit of endocrine therapy. Breast 2015; 24(Suppl 1): PG 11.03.
    1. Viale G, Regan MM, Dell'Orto P et al. . Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1–98 randomized trial. Ann Oncol 2011; 22: 2201–2207.
    1. Goodwin PJ. Obesity and insulin resistance: clinical relevance and research priorities. Breast 2015; 24(Suppl 1): PG 6.03.
    1. Shulman LN, Cirrincione CT, Berry DA et al. . Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 2012; 30: 4071–4076.
    1. Wolff AC, Blackford AL, Visvanathan K et al. . Risk of marrow neoplasms after adjuvant breast cancer therapy: The National Comprehensive Cancer Network Experience. J Clin Oncol 2015; 33: 340–348.
    1. Eckhoff L, Knoop A, Jensen MB et al. . Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 2015; 51: 292–300.
    1. de Azambuja E, Procter MJ, van Veldhuisen DJ et al. . Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014; 32: 2159–2165.
    1. Tolaney SM, Barry WT, Dang CT et al. . Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372: 134–141.
    1. Pagani O, Ruggeri M, Manunta S et al. . Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast 2015; 24: 201–207.
    1. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials. Lancet 2012; 379: 432–444.
    1. Hart CD, Di Leo A. Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. Breast 2015; 24(Suppl 1): PG 12.02.
    1. Slamon D, Eiermann W, Robert N et al. . Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273–1283.
    1. Davies C, Pan H, Godwin J et al. . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805–816.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir